Insights From Liver-Humanized Mice on Cholesterol Lipoprotein Metabolism and LXR-Agonist Pharmacodynamics in Humans by Minniti, Mirko E. et al.
656
Hepatology, Vol. 72, No. 2, 2020  
Insights From Liver-Humanized Mice 
on Cholesterol Lipoprotein Metabolism 
and LXR-Agonist Pharmacodynamics in 
Humans
Mirko E. Minniti ,1 Matteo Pedrelli,1 Lise-Lotte Vedin,1 Anne-Sophie Delbès,2 Raphaël G.P. Denis,2 Katariina Öörni,3  
Claudia Sala,4 Chiara Pirazzini,5 Divya Thiagarajan,6 Harri J. Nurmi,3,7 Markus Grompe,8,9 Kevin Mills,10 Paolo Garagnani,1,11  
Ewa C.S. Ellis ,12 Stephen C. Strom,13 Serge H. Luquet,2 Elizabeth M. Wilson,9 John Bial,9 Knut R. Steffensen,1  
and Paolo Parini1,14,15
BaCKgRoUND aND aIMS: Genetically modified mice 
have been used extensively to study human disease. However, 
the data gained are not always translatable to humans because 
of major species differences. Liver-humanized mice (LHM) 
are considered a promising model to study human hepatic 
and systemic metabolism. Therefore, we aimed to further ex-
plore their lipoprotein metabolism and to characterize key he-
patic species-related, physiological differences.
appRoaCH aND ReSUltS: Fah−/−, Rag2−/−, and Il2rg−/− 
knockout mice on the nonobese diabetic (FRGN) background 
were repopulated with primary human hepatocytes from dif-
ferent donors. Cholesterol lipoprotein profiles of LHM showed 
a human-like pattern, characterized by a high ratio of low-
density lipoprotein to high-density lipoprotein, and depend-
ency on the human donor. This pattern was determined by a 
higher level of apolipoprotein B100 in circulation, as a result 
of lower hepatic mRNA editing and low-density lipoprotein 
receptor expression, and higher levels of circulating proprotein 
convertase subtilisin/kexin type 9. As a consequence, LHM 
lipoproteins bind to human aortic proteoglycans in a pattern 
similar to human lipoproteins. Unexpectedly, cholesteryl ester 
transfer protein was not required to determine the human-
like cholesterol lipoprotein profile. Moreover, LHM treated 
with GW3965 mimicked the negative lipid outcomes of the 
first human trial of liver X receptor stimulation (i.e., a dra-
matic increase of cholesterol and triglycerides in circulation). 
Innovatively, LHM allowed the characterization of these ef-
fects at a molecular level.
CoNClUSIoNS: LHM represent an interesting translatable 
model of human hepatic and lipoprotein metabolism. Because 
several metabolic parameters displayed donor dependency, 
LHM may also be used in studies for personalized medicine. 
(Hepatology 2020;72:656-670).
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cardiometabolic diseases in general. However, the data 
gained from these studies are not always translatable 
to the clinic because of major species differences, par-
ticularly in hepatic metabolism. Therefore, the devel-
opment of translatable models to study the human 
condition is an essential step for the future of basic 
and preclinical research. In addition, the development 
and integration of personalized medicine into health 
care requires access to, standardization, and validation 
of personalized and translatable models to test and 
refine innovative therapeutic protocols.
Liver-humanized mice (LHM), in which the liver is 
repopulated with human hepatocytes, have been pro-
posed as an improved model to study human liver and 
lipoprotein metabolism.(1) One of the available mouse 
models is the FRG triple knockout (KO), characterized 
by the lack of fumarylacetoacetate hydrolase (Fah) and 
severe immunodeficiency (Rag2−/− and Il2rg−/−).(2) After 
transplantation with human hepatocytes, liver cells 
bearing functional Fah/FAH are selected,(2) resulting in 
liver chimerism of at least 80%. Moreover, backcross-
ing FRG-KO mice with the nonobese diabetic (NOD) 
strain yields FRGN mice, which are more efficient for 
xenografts and show an improved humanization.(3,4) 
These chimeric models offer the unique opportunity to 
gain insights in the species-related differences between 
human and mouse hepatic metabolism. For example, 
it is well known that cholesterol in low-density lipo-
protein (LDL) represents the major fraction of plasma 
cholesterol in humans, whereas mice are primarily a 
high-density lipoprotein (HDL) species. However, the 
underlying reasons continue to be a matter of inves-
tigation. Differences are found not only in the dis-
tribution of lipoproteins, but also in their properties 
and in the proteins modifying them. Cholesteryl ester 
transfer protein (CETP), for instance, is expressed by 
humans but not in mice, and exchanging cholesteryl 
esters from HDL particles for triglycerides in very low- 
density lipoprotein (VLDL) and LDL is considered 
the main reason for the species differences observed in 
cholesterol lipoprotein distribution.(5,6) FRG-KO mice 
engrafted with human hepatocytes were reported to 
exhibit a human-like lipoprotein profile(1) and CETP.(7) 
However, these latter results contradict other studies in 
humans showing Kupffer cells, rather than hepatocytes, 
as the main source for CETP.(8) Therefore, it is crucial 
to assess thoroughly which metabolic features are pres-
ent in humans, but not in mice, and are subsequently 
acquired by LHM.
An aspect of LHM that is intriguing in light of 
the future demands of personalized medicine is the 
ability to engraft them with human hepatocytes deriv-
ing from different donors. Because liver is a master 
regulator of metabolism, LHM may be useful to study 
individual disposition to disease, gender differences, 
and impact of risk or protective genetic variants.
Therefore, we aimed to validate LHM as a use-
ful and translatable model of human lipoprotein 
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metabolism by focusing on the liver-related species 
differences responsible for the humanization of the 
lipoprotein profile, and the variability of response 
among different human donors. In addition, LHM are 
used extensively in drug discovery and development, 
demonstrating an improved predictive capacity over 
transgenic or wild-type mice.(9) Hence, we investi-
gated whether LHM could also be used to predict the 
human response to novel therapeutic strategies, such 
as liver X receptor (LXR) agonism, which showed 
great potential when tested in classical mouse models.
Experimental Procedures
StUDy DeSIgN
The objective of this study was to corroborate 
LHM as a relevant model to study human lipopro-
tein metabolism by thorough characterization of the 
related physiological differences limiting the trans-
latability to the human condition. The primary pur-
pose was to assess which human features are acquired 
by this model and whether these are dependent on 
the human donor. Human and mouse reference sam-
ples were tested in all analyses, and FRGN mice 
transplanted with NOD mouse hepatocytes (liver- 
murinized mice, LMM) served as negative control. To 
determine lipoprotein metabolism in LHM, we ana-
lyzed the lipid lipoprotein composition, CETP, and 
phospholipid transfer protein (PLTP/Pltp) expression 
at different levels, apolipoprotein (APO) B mRNA 
editing in liver, and apolipoproteins of lipoproteins 
isolated from serum. We also assessed LDL recep-
tor (LDLR) in liver and circulating levels of human 
or mouse proprotein convertase subtilisin/kexin type 
9 (PCSK9). Lipoprotein properties such as human 
aortic proteoglycan (haPG) binding or serum cho-
lesterol efflux capacity were measured to understand 
the relevance of the changes in lipoprotein profile 
and metabolism in LHM. To investigate the use of 
LHM for elucidating the effects of LXR stimulation 
in humans, LHM (donors M1 and M3) were treated 
by gavage for 3  days (four treatments) with vehicle 
(methylcellulose 0.5% wt/vol) or 30  mg/kg/day of 
the LXR agonist GW3965. In LHM-M1 animals, 
lipoprotein and intrahepatic metabolism were inves-
tigated, the latter by measurement of liver choles-
terol precursors and composition, bile acid precursors 
and composition, and triglycerides. Moreover, gene 
expression was assessed with both RNA sequencing 
and real-time quantitative PCR analyses to identify 
the effects of LXR stimulation in human hepatocytes. 
Liver histology was analyzed in the LHM-M3 ani-
mals. Analyses were performed in a blinded fashion 
when possible. Within each group, outlier rejection 
was performed prospectively by the robust regression 
and outlier removal method (Q  =  5%) for (HDL/
LDL) cholesterol or VLDL cholesterol. Samples were 
analyzed in duplicate or triplicate, and each test was 
performed at least twice. More details are available in 
the Supporting Information.
geNeRatIoN oF tHe FRgN 
StRaIN aND HepatoCyte 
tRaNSplaNtatIoN
FRGN mice were repopulated with hepatocytes as 
described previously.(2,3) Male mice were engrafted 
with primary hepatocytes from male NOD mouse 
(LMM, n = 7) and human donor A (LHM-A, n = 4), 
donor B (LHM-B, n = 3), female donor F1 (LHM-
F1, n  =  11), female donor F2 (LHM-F2, n  =  12), 
male donor M1 (LHM-M1, n = 15), male donor M2 
(LHM-M2, n = 5), and male donor M3 (LHM-M3, 
n = 4). Hepatocytes and serum from human donors 
A and B were obtained from the Division of Surgery, 
Department of Clinical Science, Intervention and 
Technology, Karolinska Institute at Karolinska 
University Hospital Huddinge (Stockholm, Sweden), 
whereas human donor F1, F2, M1, M2 and M3 
hepatocytes were obtained from commercially avail-
able sources. FRGN mice repopulated with primary 
hepatocytes were fed a Pico Lab High Energy Mouse 
Diet 5LJ5 (LabDiet; W.F. Fisher & Son, Somerville, 
NJ). Only mice with human hepatocyte repopulation 
greater than 70% (corresponding to circulating lev-
els of human albumin > 3.5  mg/mL) were used in 
this study. The double humanized mouse (DHM) 
was engrafted with human hepatocytes from donor 
F2 and hematopoietic stem cells (DHM-F2, n = 1), 
as described.(10) Chimeric animals were generated at 
Yecuris Corp. (Tualatin, OR) or Karolinska Institute 
(Stockholm, Sweden). This study complies with 
the Declaration of Helsinki, and ethical approvals 
(2010/678-31/3, S82-13, and 2017/269-31) were 
obtained from local authorities. All animal work 
was conducted according to approved Institutional 
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Animal Care and Use Committee (Yecuris Corp.) 
protocol DN000024 and NIH OLAW assurance 
#A4664-01. The protocols follow the National 
Institutes of Health Guide for the Care and Use of 
Laboratory Animals.
QUaNtIFICatIoN oF SeRUM 
lIpopRoteIN lIpIDS
Lipoproteins were separated from 2.5 μL serum by 
size-exclusion chromatography, and lipids were quan-
tified with a real-time detection method as previously 
described.(11,12)
apoB/apob mRNa eDItINg  
aSSay
We developed in collaboration with TATAA 
Biocenter (Gothenburg, Sweden) the qPCR test of 
APOB/Apob probe SNP Assay (Cat# Apob500SNP; 
TATAA Biocenter). For details see the Supporting 
Information.
ISolatIoN oF lIpopRoteINS 
IN DeUteRIUM oXIDe/SUCRoSe 
BUFFeR
Lipoproteins from 50  μL-pooled serum samples 
were separated by sequential differential micro-ultra-
centrifugation in D2O/sucrose.
(13) To keep the initial 
proportion of lipoprotein concentration, each frac-
tion was limited to the same serum volume (50 μL).
StatIStICal aNalySIS
Due to different group sizes and a high prevalence 
of variables not normally distributed, we used a non-
parametric analysis. Data are expressed as median and 
interquartile range, with the exception of the lipopro-
tein chromatograms and data from pooled samples 
(expressed as mean  ±  SEM). To avoid false-positive 
results from the multiple testing, statistical signifi-
cance was set at the level of α  <  0.01 after Holm-
Bonferroni adjustment (α < 0.05 for post-hoc analyses). 
In the LXR study, in which fewer comparisons were 
tested, the α-value was kept to 0.05. Kruskal-Wallis 
test followed by Dunn’s multiple comparison test was 
used for multigroup comparisons. Mann-Whitney U 
Test was used for two-group comparisons. Spearman 
rank correlation analysis was used to determine asso-
ciations between continuous and ordinal parameters. 
Statistical analyses and graphs were performed using 
Statistica (TIBCO Software Inc., Palo Alto, CA) 




IN FRgN MICe IS HUMaNIZeD 
aFteR eNgRaFtMeNt WItH 
HUMaN HepatoCyteS
It is well known that humans transport plasma 
cholesterol primarily in LDL particles, whereas mice 
use HDL particles. Peripheral lipoprotein profiles 
were analyzed in LHM to understand how they 
resemble the human donor and to determine what 
contribution is made by the murine host. FRGN 
mice were transplanted with hepatocytes from human 
donor A (LHM-A, n = 4), human donor B (LHM-B, 
n = 3) and NOD mouse (LMM, n = 7), and choles-
terol lipoprotein profiles were compared. As shown 
in Fig. 1A, lipoproteins from donor A and LHM-A 
clearly displayed similar LDL profiles, with a LDL/
HDL-cholesterol ratio of 1.1 and 9.2, respectively. 
In contrast, LMM generated lipoprotein profiles 
that were HDL-dominant (LDL/HDL cholesterol 
close to 0). As observed in donor A, the LDL frac-
tion represented most of the cholesterol in LHM-A, 
whereas the HDL fraction was proportionally lower. 
Nevertheless, the cholesterol lipoprotein profile from 
LHM-A was much more similar to donor A than 
that of LMM. Similar results were observed for 
donor B and LHM-B (Supporting Fig. S1).
CHoleSteRol lIpopRoteIN 
pRoFIle IN lHM IS DepeNDeNt 
oN tHe HUMaN DoNoR
To extend our investigation on donor specificity, 36 
FRGN male mice were divided into four groups and 
repopulated with primary human hepatocytes from 
two female (F1 and F2) and two male donors (M1 
and M2). These mice were highly humanized (>70%), 
and a summary of the genetic data of human donors 
is available in Supporting Table S1. As shown in 
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Fig. 1B-E, each group displayed a typical human lipo-
protein profile with higher proportion of cholesterol 
in LDL than in HDL. Moreover, the profiles were 
highly consistent with small intragroup variability. For 
instance, LHM-M2 showed a profile characteristic 
of a subject with a dyslipidemia (i.e., equal amount 
of cholesterol in VLDL and LDL). In addition, the 
differences originated from the human donors were 
statistically significant (P  <  0.01) for all other main 
lipid lipoprotein components (Table 1). Among all of 
the groups, LHM-F2 displayed the highest amount of 
serum total cholesterol (4.7  mmol/L), in contrast to 
FIg. 1. Cholesterol lipoprotein profile in LHM is humanized and depends on the human donor’s hepatocytes. Cholesterol lipoprotein 
profiles were assessed by size-exclusion chromatography. (A) Cholesterol profile of the human donor A (n = 1), of the LHM engrafted 
with his primary hepatocytes (LHM-A, n = 4), and of LMM (n = 7). Cholesterol profiles of LHM transplanted with F1 (n = 11) (B), F2 
(n = 12) (C), M1 (n = 8) (D), or M2 (n = 5) (E) hepatocytes. The profiles represent the mean chromatograms, and the shaded area around 
them represents the SEM. See Supporting Fig. S1 for the cholesterol profiles of human donor B and LHM-B, Supporting Fig. S2 for the 
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LHM-F1, which showed the lowest total cholesterol 
content (2.6  mmol/L). Importantly, the lipid levels 
observed were within the normal human physiologi-
cal range (and higher compared with wild-type mice). 
It is necessary to emphasize that the differences and 
precision of the lipoprotein composition were clearly 
dependent on the hepatocytes of the human donor, 
and not directly correlative of the level of humaniza-
tion (Supporting Fig. S2).
HUMaNIZatIoN oF 
lIpopRoteIN pRoFIle IS 
INDepeNDeNt oF Cetp
Plasma lipid transfer proteins, such as CETP and 
PLTP, are liver-derived proteins that are important 
for lipoprotein metabolism. Because CETP is not 
expressed in mice, it is believed that its presence in 
humans is the main reason for the typical LDL dis-
tribution of cholesterol.(5) To understand the drivers 
of humanization of lipoprotein profiles in LHM, we 
assessed the hepatic mRNA and protein expression 
of CETP, as well as circulating protein and activity. 
Surprisingly, we did not detect CETP mRNA in 
liver, nor protein expression in liver or in circulation 
(Supporting Table S2 and Fig. S3), even after using 
two different primer pairs for real-time quantita-
tive PCR, two different CETP antibodies, and two 
different enzyme-linked immunosorbent assay kits. 
Moreover, CETP activity in circulation was present 
only in humans and not in LHM or LMM (Supporting 
Table S2). We had the possibility to analyze the serum 
from one FRGN mouse co-transplanted with human 
hematopoietic stem cells and hepatocytes (DHM) 
from donor F2 (DHM-F2), which presents human 
Kupffer cells in the chimeric liver.(10) Therefore, as a 
proof of concept that CETP does not originate from 
hepatocytes, we analyzed CETP activity in DHM-
F2. As shown in Fig. 2, DHM-F2 exhibited CETP 
activity in circulation, and its levels were about 50% 
of those observed in the human reference sample. To 
understand the impact of the appearance of CETP 
activity, we analyzed the cholesterol lipoprotein pro-
file of DHM-F2 and compared it with the LHM-F2 
taBle 1. lipid levels in lipoproteins of lHM Receiving Hepatocytes From Different Donors
LHM-F1 (n = 11) LHM-F2 (n = 12) LHM-M1 (n = 8) LHM-M2 (n = 5) Kruskal-Wallis Test
Total Cholesterol (mmol/L) 2.6 (0.5) 4.7 (1.0) 3.1 (0.9) 4.0 (0.6) P < 0.01
VLDL/remnants-C (mmol/L) 0.5 (0.2) 0.4 (0.1) 0.4 (0.3) 1.5 (0.4) P < 0.01
LDL-C (mmol/L) 1.7 (0.4) 2.9 (1.0) 2.4 (0.6) 2.4 (0.5) P < 0.01
HDL-C (mmol/L) 0.4 (0.2) 1.4 (1.1) 0.2 (0.2) 0.3 (0.1) P < 0.01
(LDL/HDL)-C 4 (2) 2 (2) 17 (19) 11 (5) P < 0.01
Total CE (mmol/L) 2.1 (0.6) 3.8 (0.8) 2.4 (0.7) 3.2 (0.2) P < 0.01
VLDL/remnants-CE (mmol/L) 0.4 (0.2) 0.3 (0.1) 0.3 (0.2) 1.1 (0.3) P < 0.01
LDL-CE (mmol/L) 1.3 (0.4) 2.3 (0.7) 1.9 (0.5) 1.9 (0.3) P < 0.01
HDL-CE (mmol/L) 0.3 (0.1) 1.1 (0.9) 0.1 (0.2) 0.3 (0.1) P < 0.01
Total FC (mmol/L) 0.5 (0.1) 0.9 (0.2) 0.7 (0.2) 0.9 (0.4) P < 0.01
VLDL/remnants-FC (mmol/L) 0.1 (0.0) 0.1 (0.0) 0.1 (0.1) 0.4 (0.1) P < 0.01
LDL-FC (mmol/L) 0.3 (0.1) 0.6 (0.2) 0.5 (0.1) 0.5 (0.2) P < 0.01
HDL-FC (mmol/L) 0.1 (0.1) 0.3 (0.2) 0.1 (0.1) 0.1 (0.0) P < 0.01
Total TG (mmol/L) 0.8 (0.2) 1.2 (0.4) 0.8 (0.4) 0.9 (0.1) P < 0.01
VLDL/remnants-TG (mmol/L) 0.3 (0.1) 0.4 (0.2) 0.3 (0.2) 0.6 (0.0) P < 0.01
LDL-TG (mmol/L) 0.3 (0.1) 0.7 (0.2) 0.4 (0.2) 0.3 (0.0) P < 0.01
HDL-TG (mmol/L) 0.1 (0.1) 0.1 (0.1) 0.1 (0.0) 0.1 (0.0) P = 0.24
Total PL (mmol/L) 1.8 (0.2) 3.5 (0.6) 1.9 (0.5) 2.5 (0.8) P < 0.01
VLDL/remnants-PL (mmol/L) 0.2 (0.1) 0.2 (0.1) 0.2 (0.2) 0.9 (0.2) P < 0.01
LDL-PL (mmol/L) 0.8 (0.2) 1.1 (0.5) 1.0 (0.3) 1.3 (0.2) P < 0.01
HDL-PL (mmol/L) 0.8 (0.3) 2.1 (0.7) 0.6 (0.4) 0.7 (0.2) P < 0.01
Note: Data are presented as the median and interquartile range. Kruskal-Wallis test followed by Dunn’s multiple comparison test showed 
significant differences (P < 0.01) in all lipoprotein lipids (except for HDL triglycerides).
Abbreviations: C, cholesterol; CE, cholesteryl esters; FC, free (or unesterified) cholesterol; PL, phospholipids; TG, triglycerides.
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group, whose mice were bearing only hepatocytes 
from the same donor. Consistently with the known 
function of CETP, DHM-F2 exhibited higher levels 
of cholesterol in the APOB-containing particles (i.e., 
VLDL and LDL) and lower levels of cholesterol in 
the HDL fraction (Fig. 2).
PLTP transfers phospholipids from triglyceride- 
rich lipoproteins to HDL. LHM expressed both 
human PLTP and mouse Pltp mRNA in liver, although 
the human transcript was at low levels (Supporting 
Fig. S4). In LHM, PLTP activity in circulation was 
at comparable levels to those observed in the human 
reference sample, whereas it was lower compared to 
LMM (−57% ± 15%) and to the wild-type mouse ref-
erence (−67% ± 12%) (Table 2).
lHM eXpReSS HIgHeR leVelS 
oF CIRCUlatINg apoB100 aND 
pCSK9, aND loWeR HepatIC 
lDlR CoMpaReD WItH lMM
Because the humanization of LHM lipoprotein 
profile does not require CETP, we hypothesized 
that the distribution of cholesterol predominantly in 
LDL particles could result from a higher presence of 
APOB100 in circulation. Editing of APOB mRNA to 
generate APOB48 does not occur in human liver,(14) 
and lipoproteins containing APOB100 instead of 
APOB48 have higher half-life in circulation.(15) We 
therefore hypothesized that hepatic APOB mRNA 
editing would not be present in LHM. Hence, a 
real-time quantitative PCR–based assay to evaluate 
the mRNA editing of both APOB and Apob in tandem 
was specifically developed. As expected, we observed 
a markedly lower editing of liver APOB mRNA in 
LHM compared with LMM (P  <  0.01) (Fig. 3A). 
Subsequently, we investigated the APO composition 
in lipoproteins isolated from serum, paying particular 
attention to APOB. As shown in Fig. 3B for LDL 
and HDL (and in Supporting Fig. S5 for VLDL), 
we isolated the major APOs specific for lipoprotein 
fractions. We could identify both APOB100 and, to a 
lesser extent, APOB48 in all LDL samples from LHM 
(band quantification in Supporting Fig. S6). However, 
in LHM the APOB100 levels were more similar to 
those of the human reference sample than to the mouse 
FIg. 2. The chimeric mouse model of human liver with hepatocytes and Kupffer cells exhibits CETP activity and changes in the 
distribution of lipoprotein cholesterol. DHM was transplanted with human hepatocytes from donor F2 and hematopoietic stem cells 
(DHM-F2, n = 1). CETP activity was analyzed with a fluorometric assay in kinetic measurement. Data are presented as mean and SEM 
from three different triplicates. Compared with LHM-F2 (n  =  12), DHM-F2 also exhibited changes in cholesterol levels that were 
compatible with CETP activity in circulation. Cholesterol profiles represent the mean chromatograms, and the shaded area around them 
represents SEM. See Supporting Fig. S3 and Supporting Table S2 for CETP expression in LHM.
taBle 2. pltp activity in Circulation of lHM








Note: Sera were pooled based on the group, and phospholipid 
transfer was analyzed with a fluorometric assay in kinetic meas-
urement. Data are presented as mean ± SEM from three different 
triplicates. Human and mouse sera are reference samples. LMM 
served as negative control. See Supporting Fig. S4 for PLTP/Pltp 
expression in LHM.
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reference and LMM (Fig. 3B and Supporting Fig. 
S6). Moreover, the distribution of APOs was donor- 
specific: APOA1 (band at 25-30 kDa) was present in 
the HDL from all samples, but only present in the 
LDL from LHM-F2 (Fig. 3B), suggesting the pres-
ence of large and buoyant HDL that float at the den-
sity of LDL particles (1.019-1.063  g/mL) specifically 
for this human donor. In LHM, we could also identify 
lipoprotein (a) (Lp[a]) in circulation, which is expressed 
in humans but not in mice (Supporting Fig. S7).
Knowing the lower hepatic LDL clearance in 
humans compared with mice,(16) we quantified the 
protein expression of human and mouse LDLR in 
the liver from LHM and LMM. The LHM-F2 pool 
had approximately 75% lower levels of LDLR in liver 
compared with the LMM pool (Fig. 3C). Because 
PCSK9 regulates the protein expression of LDLR in 
both humans and mice, we assessed the circulating lev-
els of human or mouse PCSK9 in LHM and LMM. 
In LHM samples, the levels of human PCSK9 were 
donor-dependent. On the contrary, mouse PCSK9 
levels were similar between LHM and LMM, with the 
loss of donor dependency (Fig. 3D). As result, LHM 
exhibited higher total levels of circulating PCSK9 
than LMM, which contributes to the explanation of 
the lower expression of hepatic LDLR in LHM.
FIg. 3. APOB phenotype in LHM. (A) Hepatic APOB mRNA editing quantified by real-time quantitative PCR–based assay. Data are 
presented as the median (depicted by the line) of scattered dots. Mann-Whitney U Test; **P < 0.01. Human and mouse served as reference 
samples. Samples below the limit of quantification (LOQ, 10%) were set equal to the LOQ in both statistical and graphical analyses. 
(B) Apolipoprotein composition of LDL and HDL (see Supporting Fig. S5 for VLDL and Supporting Fig. S6 for the quantification of 
APOB bands in LDL). Lipoproteins were isolated from pooled sera and underwent 4%-12% Bis-Tris gel electrophoresis and staining 
with Coomassie G-250. Human and mouse sera are reference samples, and LMM served as negative control. Major apolipoproteins were 
identified by molecular weight. See Supporting Fig. S7 for Lp(a) in LHM. (C) Hepatic LDLR expression. Data are presented as mean and 
SEM from three different replicates. Quantification was done by western blot with sample titration using an antibody reactive to human 
and mouse LDLR. (D) Human or mouse circulating PCSK9 quantified by enzyme-linked immunosorbent assay. Data are presented as 
the median (depicted by the line) of scattered dots. Kruskal-Wallis test was followed by multiple comparisons; *P < 0.05. LMM served as 
specificity control in the human PCSK9 kit. Because of the lack of a common calibrator, concentrations from human or mouse PCSK9 
kits could not be converted in molar units, annulling their direct comparison. Abbreviation: SAA, serum amyloid A.
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lHM lIpopRoteINS 
BIND HUMaN aoRtIC 
pRoteoglyCaNS SIMIlaRly to 
HUMaN lIpopRoteINS
To understand the relevance of the changes in 
lipoprotein profiles and to further characterize the 
lipoproteins of LHM, we assessed in vitro their 
binding to haPG. This property can predict the 
atherogenic potential of lipoproteins in circula-
tion, as haPG binding in vivo is the first step in 
the response-to-retention hypothesis of athero-
genesis.(17,18) LMM, which exhibited low levels of 
APOB100 in circulation, displayed almost no haPG 
binding, whereas LHM displayed haPG binding 
similar to that observed in humans (Fig. 4). Again, 
donor-related differences were present and were 
modified after correction for serum total choles-
terol (Fig. 4), suggesting the presence of a different 
number of lipoproteins with different characteristics 
depending on the human donor.
lXR aCtIVatIoN DeteRMINeS 
aN UNFaVoRaBle pHeNotype 
oF CIRCUlatINg aND HepatIC 
lIpIDS IN lHM
The human trial with the LXR agonist BMS-
852927 showed negative outcomes regarding plasma 
lipoprotein and liver lipids.(19) This result was likely 
attributable to species-related differences between 
humans and mice. To assess the potential of LHM 
as a model in which to predict the pharmacodynam-
ics of compounds aimed to target nuclear receptors 
in human liver, we treated LHM-M1 mice with 
the LXR agonist GW3965. As shown in Fig. 5A, 
LXR activation in LHM-M1 induced a substan-
tial increase of serum cholesterol and triglycerides 
(P  <  0.01), as reported in hamster and cynomol-
gus monkey.(20) Interestingly, the highest propor-
tional increase for cholesterol was not observed in 
the LDL fraction (+144%), but in the VLDL frac-
tion (+309%). To investigate the reasons underlying 
the increase in serum cholesterol following LXR 
stimulation, we explored LDLR expression. LDLR 
mRNA in liver decreased 60% after treatment with 
GW3965 (Supporting Table S3), although its protein 
levels were unchanged (Supporting Fig. S8). PCSK9 
is an LXR-independent regulator of LDLR (and 
APOB) catabolism, and its hepatic mRNA or circu-
lating protein levels did not change after treatment 
with GW3965 (Supporting Table S3 and Fig. S9). 
MYLIP (myosin regulatory light chain interacting 
protein, also known as IDOL, inducible degrader of 
LDLR) is an LXR-target gene degrading LDLR(21); 
however, no differences were found at the hepatic 
mRNA level in LHM-M1 after LXR stimulation 
(Supporting Table S3). CETP is another LXR tar-
get gene,(20) but we could not detect any mRNA 
(Supporting Table S3) or protein (Supporting Fig. S3) 
in the liver of LHM-M1 treated with GW3965, 
eliminating the possibility of evaluating any effect 
on this gene. As shown in Fig. 5B, we assessed the 
haPG binding of lipoproteins, which was higher 
FIg. 4. LHM lipoproteins bind haPG similarly to human lipoproteins. One microliter  of serum was added to the immobilized 
proteoglycans, and after incubation the amount of bound cholesterol was determined. To correct for differences in serum cholesterol 
in each individual sample, the bound cholesterol was divided for the concentration of serum cholesterol. Data are presented as the 
median (depicted by the line) of scattered dots. Kruskal-Wallis test was followed by multiple comparisons test; *P < 0.05, **P < 0.01, and 
***P < 0.001. Human sera are reference samples; LMM served as negative control.
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after LXR stimulation. Nonetheless, lipoproteins in 
LHM-M1 treated with GW3965 maintained the 
same binding capacity after correction for serum 
cholesterol. We also analyzed the serum choles-
terol efflux capacity (Fig. 5C), as LXR activation is 
known to affect this property in mice.(22) GW3965 
stimulation increased (P  =  0.05) the adenosine tri-
phosphate binding cassette subfamily A member 1 
(ABCA1)-mediated efflux to lipid-poor APOA1 or 
nascent/preβ-HDL. Aqueous diffusion, the concen-
tration gradient-driven cholesterol transport toward 
mature HDL, was significantly increased in LHM-
M1 treated with GW3965 (P < 0.01).
Mirroring the lipoprotein phenotype observed in 
circulation, LXR activation by GW3965 in LHM-
M1 also resulted in intrahepatic accumulation of tri-
glycerides and cholesteryl esters (Fig. 5D), without 
affecting the levels of free (or unesterified) cholesterol 
(Fig. 5E) or inducing liver damage (circulating transam-
inases in Supporting Fig. S10). LXR activation greatly 
reduced bile acid synthesis evaluated by the levels of 
7alpha-hydroxy-4-cholesten-3-one (C4) (Fig. 5F) and 
glycocholic acid (Supporting Fig. S11) in the liver. 
LHM-M1 treated with GW3965 had lower cholesterol 
biosynthesis (Fig. 5G), mediated by down-regulation 
of the sterol regulatory element binding transcription 
factor 2 (SREBF2) pathway (Supporting Table S3). 
Moreover, despite a 7-fold induction of sterol regula-
tory element binding transcription factor 1 (SREBF1) 
variant c, its target genes involved in de novo lipogen-
esis were not up-regulated (Supporting Table S3). The 
adverse changes in lipoprotein and liver metabolism were 
likely the result of the up-regulation of lipid droplet– 
associated genes and the down-regulation of genes 
involved in neutral lipid hydrolysis, together with the 
down-regulation of cytochrome P450 family 7 subfam-
ily A member 1 (CYP7A1), the rate-limiting enzyme 
in neutral bile acid biosynthetic pathway (Supporting 
Table S3). A graphical representation of the effects of 
LXR stimulation on hepatic gene expression leading to 
the adverse changes in lipoprotein and lipid metabo-
lism is presented in Supporting Fig. S12. Furthermore, 
a transcriptomic analysis of human and mouse genes in 
LHM-M1 chimeric liver following LXR stimulation is 
available in Supporting Fig. S13.
To explore the potential development of steato-
sis and compensatory regeneration following LXR 
stimulation, we characterized the liver histology of 
another batch of animals (LHM-M3) treated with 
GW3965. As shown in Fig. 6, LXR stimulation by 
GW3965 induced moderate macrovesicular steatosis 
and occasional ballooning. Changes in cell prolifera-
tion were not detected.
Gene-expression analysis in LHM-M1 small intes-
tine revealed the up-regulation of LXR target genes 
following treatment with GW3965, but no effect on 
FXR-target genes (Supporting Table S4). This suggests 
neither alteration in the intestinal response of LXR 
activation, nor in the cross-talk between the liver and 
the gut in LHM, apart from the previously reported 
unresponsiveness of human hepatocytes to the intesti-
nal murine fibroblast growth factor (FGF) 15.(1,23)
Discussion
The continuous growth in the prevalence of car-
diometabolic disease, the development of new ther-
apeutic approaches, and the need to implement 
personalized medicine in health care systems demand 
the development of advanced preclinical research 
models. In these models, it should be possible to elu-
cidate the uniqueness of the individual and to obtain 
results that are translatable to the human patients. The 
FIg. 5. LXR stimulation by GW3965 determines an unfavorable phenotype of circulating and hepatic lipids in LHM-M1. FRGN 
mice were repopulated with hepatocytes from the human donor M1 (LHM-M1) and treated with either vehicle (n = 6) or GW3965 
(n = 7). (A) Cholesterol and triglyceride lipoprotein distribution in serum. Bar data are presented as the median and interquartile range. 
(B) Lipoprotein binding to haPG. Data are presented as the median (depicted by the line) of scattered dots. (C) Serum cholesterol efflux 
capacity through adenosine triphosphate binding cassette subfamily A member 1 (ABCA1) or aqueous diffusion. Data are presented as 
the median (depicted by the line) of scattered dots. (D) Triglycerides and cholesteryl esters in liver. Data are presented as the median 
(depicted by the line) of scattered dots. (E) Free (or unesterified) cholesterol in the liver. Data are presented as the median (depicted by 
the line) of scattered dots. (F) 7alpha-hydroxy-4-cholesten-3-one (C4) in liver. Data are presented as the median (depicted by the line) 
of scattered dots. (G) Cholesterol precursors lathosterol and lanosterol in the liver. Data are presented as the median (depicted by the 
line) of scattered dots. All data were analyzed by Mann-Whitney U Test; *P < 0.05 and **P < 0.01. See also Supporting Fig. S8 (hepatic 
LDLR), Supporting Fig. S9 (circulating PCSK9), Supporting Fig. S10 (circulating transaminases), Supporting Fig. S11 (liver bile acids), 
Supporting Fig. S12 (graphical scheme of LXR stimulation in human liver), Supporting Fig. S13 (human and mouse liver transcriptome), 
Supporting Table S3 (hepatic expression of human genes), and Supporting Table S4 (small intestine expression of mouse genes).
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use of chimeric models such as LHM is a clear step 
toward this direction. Donor-dependent phenotypes 
and the unfavorable outcomes of the clinical trial 
using LXR agonist were observed and reproduced in 
LHM. Furthermore, the use of LHM models allowed 
a better understanding of human cholesterol lipo-
protein metabolism and explained some of the liver- 
related species differences between humans and mice.
CETP has been recognized as one of the main 
protein responsible for the difference in cholesterol 
distribution between humans (LDL animals) and 
mice (HDL—or rather non-LDL—animals).(5) By 
exchanging triglycerides in APOB-containing lipo-
proteins for cholesteryl esters in HDL, CETP is sup-
posed to increase the cholesterol content of VLDL 
and LDL.(5,6) For this reason, this protein is con-
sidered proatherogenic and pharmacologically targ-
etable.(5,6) CETP is produced predominantly by the 
spleen, adipose tissue and liver in humans, but not in 
mice. Despite the attainment of a human-like lipo-
protein phenotype in mice repopulated with hepato-
cytes from four different human donors, we could not 
detect CETP protein or activity in the circulation. 
To confirm our findings, we also assayed the hepatic 
mRNA and protein expression of CETP and found 
none. Our results reflect what has been reported in 
humans, namely that CETP expression is not pres-
ent in hepatocytes and is confined to Kupffer cells in 
the liver and to circulating macrophages.(8) Moreover, 
when comparing the double chimeric mouse model 
of human liver and immune system (DHM-F2) with 
chimeric mice of only human liver receiving hepato-
cytes from the same donor (LHM-F2), an increase 
of cholesterol in the APOB-containing lipoproteins 
accompanied by a decrease of cholesterol in HDL was 
observed. These results are in line with the pheno-
type of subjects bearing CETP homozygous loss-of-
function mutations, which consists of low LDL and 
high HDL cholesterol levels.(24,25) Hence, our find-
ings provide the ultimate proof that liver parenchy-
mal hepatocytes do not contribute to CETP activity 
in circulation, which is only detected when human 
Kupffer cells are present.
In contrast to what was observed for CETP, 
we could detect in circulation the activity of PLTP 
(another plasma lipid transfer protein) to a compara-
ble extent in both humans and LHM. The levels of 
PLTP activity were about one-fifth of those observed 
in LMM or wild-type mice, which are known to 
have higher PLTP activity than humans. Hepatic 
PLTP mRNA was extremely low in LHM, in con-
trast to Pltp mRNA, which was similar to LMM. 
Because the remaining mouse hepatocytes in our 
highly repopulated LHM represent less than 10%-
15% of parenchymal cells, their contribution to PLTP 
activity in circulation can be considered minor. Thus, 
FIg. 6. LXR stimulation by GW3965 results in moderate steatosis in LHM-M3. FRGN mice were repopulated with hepatocytes from 
the human donor M3 (LHM-M3) and treated with either vehicle (n = 2) or GW3965 (n = 2). LXR stimulation in LHM-M3 determined 
higher levels of cholesterol and triglycerides both in serum (driven by the accumulation in VLDL and LDL) and in liver (Supporting Fig. 
S14). The liver left-lateral lobe was paraffin-embedded and slices were stained with hematoxylin and eosin. Representative images from 
one mouse per group are shown (scale bar = 50 µm). (A) Almost no signs of steatosis were observed in the vehicle group. (B) After LXR 
stimulation, predominantly moderate multifocal macrovesicular steatosis (sometimes hinting toward microvesicular) and rare ballooning 
could be appreciated. In both groups, no prominent/frequent mitotic figures were detected in human hepatocytes.
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our data suggest that hepatocytes are great contrib-
utors of PLTP activity in mouse, despite the much 
lower expression of Pltp in liver compared with other 
organs.(26) As far as the effects of the reduction in 
PLTP activity in LHM, Pltp−/− mouse models show 
decreased levels of cholesterol in HDL, which accu-
mulates in VLDL and LDL without an increase in 
plasma APOB levels.(27) However, heterozygous 
Pltp+/- mice do not exhibit differences in the distribu-
tion of cholesterol in lipoproteins compared with wild 
type.(27) Our results therefore suggest that PLTP does 
not greatly contribute to the generation of the human-
like cholesterol lipoprotein phenotype of LHM.
APOB lipoproteins and mRNA editing have 
been studied thoroughly in humans and other mam-
mals.(14,28,29) In both human and mice, APOB100 is 
the full-size protein. APOB mRNA can be edited 
by APOB mRNA-editing enzyme catalytic subunit 
1 (APOBEC1), a process producing APOB48, which 
lacks the C-terminus. In humans, APOB mRNA 
editing does not occur in the liver, but only in the 
intestine. In contrast, mice can edit Apob mRNA in 
both organs.(14) Because APOB100 and APOB48 are 
known to confer different properties to lipoproteins,(15) 
several models have been generated to mimic in mice 
the human physiology or pathology, such as Apobec1−/− 
and APOB100-only mice, which both produce only 
APOB100.(30,31) However, both models acquire the 
typical LDL profile only when bred with Ldlr−/− mice, 
resulting in a dramatically nonphysiologic impaired 
uptake of APOB-containing lipoproteins from the 
circulation.(32,33) Hence, the greatly reduced hepatic 
APOB mRNA editing and the lower LDLR protein 
expression in liver—the latter mediated by higher lev-
els of circulating PCSK9—appear to be the principal 
drivers in humanizing the cholesterol lipoprotein phe-
notype of LHM. Moreover, the translatability to the 
human condition of the humanized lipoprotein profile 
in LHM is corroborated by the observation of a lipo-
protein binding to haPG that is similar to the one 
observed in human reference samples.
LHM were also tested as a translatable human 
model of pharmacodynamics. The clinical trial testing 
the effect of an LXR agonist on lipid and lipopro-
tein metabolism was prematurely terminated princi-
pally because of the increase in plasma cholesterol and 
triglycerides.(19) In parallel to what was observed in 
humans, treatment with the LXR agonist GW3965 
resulted in severe hyperlipidemia in LHM. The 
strategy of targeting LXR to decrease atherosclerosis 
originated from different mouse models: C57BL/6 
mice treated with GW3965 showed an increase of 
cholesterol in HDL,(34) and in hypercholesterolemic 
Ldlr−/− or Apoe−/− mouse, LXR activation could inhibit 
atherosclerosis.(35) Increase of cholesterol in LDL was 
only observed in species expressing CETP (i.e., ham-
ster, cynomolgus monkey, and human).(19,36) Because 
CETP is an LXR-target gene, it was suggested that 
its up-regulation followed by pharmacological stimu-
lation of LXR represented one of the main causes for 
the increase of cholesterol in LDL. Despite the lack 
of CETP expression, LHM displayed severe hyper-
cholesterolemia after LXR activation, confirming the 
contribution of additional negative effects on choles-
terol metabolism, as previously discussed.(36)
CYP7A1 up-regulation by LXR stimulation is 
species-dependent and is absent in primary human 
hepatocytes.(37) In our LHM model, LXR stim-
ulation decreased CYP7A1 mRNA levels, which 
translated into a decreased bile acid synthesis via 
the neutral pathway. This was the result of the up- 
regulation of nuclear receptor subfamily 0 group B 
member 2 (NR0B2)/small heterodimer partner (SHP) 
and FGF19. Consequently, cholesterol accumulated in 
the liver and down-regulated SREBF2 and its target 
genes (e.g., 3-hydroxy-3-methylglutaryl-CoA reduc-
tase [HMGCR] and LDLR). The triglyceride accu-
mulation in the liver of LHM treated with GW3965 
is likely independent on de novo lipogenesis despite an 
increase in mRNA levels of SREBF1 variant c, sug-
gesting a lack of activation of this transcription factor. 
The increased hepatic triglycerides appear to be the 
result of a reduced hydrolysis of neutral lipids: PLIN2 
(perilipin 2) and CIDEC (cell death-inducing DFFA-
like effector c)—two lipid droplet–associated genes 
limiting the neutral lipids hydrolysis—were indeed 
up-regulated in parallel to a down-regulation of sev-
eral carboxylesterases and lipases. Thus, we describe 
the unexpected molecular effects of LXR activation in 
human hepatocytes (Supporting Fig. S12), contribut-
ing to the explanation of the severe combined hyper-
lipidemia and triglyceride accumulation in the liver 
following LXR stimulation in humans.(19)
From our study, it is clear that FRGN mice receiv-
ing human hepatocytes display several parameters 
(including lipoprotein levels and properties, apolipo-
protein distribution, circulating PCSK9, and Lp[a]) 
based on the human donor and independently of the 
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degree of humanization. Therefore, LHM can be used 
in several preclinical settings to monitor the response 
based on the donor’s hepatocytes, allowing an efficient 
combination of translatable and personalized studies. 
Although examples of such applications are already 
available,(7,38) major limitations for the translatabil-
ity of the model come in the form of residual activity 
of the recipient mouse liver, the interaction between 
donor–recipient tissues, and the peripheral metabo-
lism of the recipient. The latter, for instance, is likely 
responsible for the differences observed in the choles-
terol lipoprotein profile of donors A and B and the 
LHM transplanted with their hepatocytes (LHM-A 
and LHM-B). In addition, as shown here for CETP, 
not all liver-related factors are acquired by LHM (with-
out further humanization of the immune system). This 
aspect has to be considered also in the use of LHM to 
study cardiometabolic diseases with an inflammatory 
component such as atherosclerosis and nonalcoholic 
steatohepatitis, wherein the model immunodeficiency 
may prevent the achievement of a full disease spec-
trum. Even so, LHM represent an improvement in 
terms of human translatability compared with the use 
of ordinary wild-type or genetically modified mouse 
models, paving the way for a preclinical approach for 
pharmacological and personalized research.
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